Celavie Biosciences Information Kit
Advancing Beyond Mainstream Stem Cell Technology
Celavie Biosciences is developing breakthrough regenerative stem cell therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS). The unmet medical needs for these conditions are significant as these diseases result in loss of basic function or mortality.
In addition to human applications, Celavie’s subsidiary, Celavet, has demonstrated restoring function in serious veterinary diseases. We are changing lives and restoring hope by changing the paradigm of stem cell technology.
Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit
CEO Sandy Solmon to Present on Celavie’s Stem Cell Therapies at Upcoming Conferences in New York and Barcelona
OXNARD, CA – January 22, 2020 – Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled “Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients,” at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.
Regenerative Stem Cell Therapy Pioneer, Celavie Biosciences, LLC, to Attend Cell & Gene Meeting on the Mesa on October 2 – 4 in Carlsbad, California
OXNARD, CA – October 1, 2019
Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, announced today their attendance at the Alliance of Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Mesa to be held October 2nd – 4th in Carlsbad, California.
Novel cells offer functional and structural restoration advantages for transplantation and therapy
OXNARD, Calif., February 21, 2017—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, received approval from the Center for Veterinary Medicine (CVM) for product characterization of its equine OK100 stem cells. Celavet’s donor selection criteria were approved by the CVM last August. These approvals mark significant progress towards pivotal studies for the OK100 stem cells, proposed to treat tendinitis (e.g., tendon injuries, bowed tendons, etc.) in horses.
Celavie has targeted Parkinson’s disease (PD) as the first human application of its stem cells (OK99). Parkinson’s disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson’s disease. The risk of developing Parkinson’s is about 1 percent at age 60. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.
Celavie Biosciences Adds Strategic Business Development Team to Bring Novel Stem Cell Technology to Market
OXNARD, Calif., Sept. 22, 2016—Celavie Biosciences LLC welcomed a team of leaders in market strategy, medical technology, pharmaceutical R&D, regulations, and product commercialization to help bring their novel stem cell technology to market. Celavie is working on stem cell-based regenerative therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS), for which there are no long-term treatments or cures.
Celavie Biosciences Awarded U.S. Patents for Stem Cell Technology with Applications for Central Nervous System Disorders
Novel cells offer functional and structural restoration advantages for transplantation and therapy
OXNARD, Calif., September 13, 2016—Regenerative medicine company Celavie Biosciences LLC, announced that the U.S. Patent and Trademark Office issued patents for its pluripotent stem cells with applications for a range of disorders of the central nervous system (CNS), including Parkinson’s disease.
CVM approval moves novel stem cell therapy one step closer to restoring health and mobility in horses
OXNARD, Calif., Aug. 12, 2016—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, received approval from the Center for Veterinary Medicine (CVM) for the donor selection criteria of its equine OK100 stem cells. The Investigational New Animal Drug (INAD) file for the OK100 stem cells is proposed to treat tendinitis (e.g., tendon injuries, bowed tendons, etc.) in horses.
New stem cell technology offers potential to revolutionize regenerative medicine
OXNARD, Calif., Dec. 14, 2015—Regenerative medicine start-up Celavie Biosciences LLC has conducted its first clinical trial to evaluate the safety of their stem cells in treating eight patients suffering from Parkinson’s disease (PD). Seven of the eight patients completed first-year follow-up. No lasting adverse effects or complications over period of more than two years were observed.
Regenerative medicine start-up studies over 400 horses with tendon and ligament injuries
OXNARD, Calif., December 15, 2013—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, successfully completed a multicenter, open label study investigating the treatment of equine tendon and ligament injuries with Celavet’s OK100 stem cells on more than 400 horses.
Regenerative medicine start-up granted compassionate use by CVM to aid animal with severe burns
OXNARD, Calif., Aug. 31, 2011—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, provided the undifferentiated stem cells successfully used for the treatment of a pit bull with severe burns. Collaborators Dr. Boyd Wagner of Wyomissing Animal Hospital and Dr. Oleg Kopyov of Celavet administered the treatment using a new stem cell technology and a newly created protocol, which resulted in near-total restoration of damaged tissue.
Unique pluripotent stem cells show favorable structural improvements to damaged tendons
OXNARD, Calif., March 3, 2010—A recent study from Celavet Inc., a subsidiary of Celavie Biosciences LLC, demonstrates promising indications for the efficacy of pluripotent stem cells in the treatment of tendon injuries in horses. Conducted at Cornell University’s College of Veterinary Medicine by Dr. Alan Nixon, the equine study investigates the effect of Celavet’s undifferentiated stem cells versus placebo controls in acute tendonitis lesions in horses’ superficial flexor tendons.
Medical team seeks advances beyond mainstream stem cell
technology to cure degenerative diseases and injuries
OXNARD, Calif., January 10, 2010—Regenerative medicine start-up Celavie Biosciences LLC has appointed three prestigious medical innovators to its advisory team. The company’s R&D focuses on using regenerative stem cell therapies to repair tissues that have been damaged by disorders of the central nervous system by use, trauma, or chronic disease, such as Parkinson’s and Huntington’s diseases, which have no long-term treatments or cures.
U.S. Patent Issued to Celavie Biosciences for Novel Method of Pluripotent Stem Cell and Neural Progenitor Cell Propagation
Innovation advances applications of stem cells in regenerative medicine sector
OXNARD, Calif., Dec. 15, 2009—The U.S. Patent and Trademark Office issued a patent to regenerative medicine company Celavie Biosciences LLC for novel propagation and transplantation methods of pluripotent stem cells (PSC) and neural progenitor cells (NPC) with applications for therapeutic, diagnostic, and research purposes in the treatment of degenerative diseases.
Repair of Equine Connective Soft Tissue Injuries Investigated in Pilot Study Utilizing Novel Stem Cells
Regenerative medicine start-up demonstrates efficacy and safety
OXNARD, Calif., August 19, 2008—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, conducted a successful pilot study of Celavet’s OK100 stem cells to investigate safety, efficacy, and prospective methodology for use of undifferentiated stem cells in the repair of equine connective soft tissue injuries.
New stem cell technology tested as innovative treatment for equine injuries
OXNARD, Calif., April 14, 2008—Regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, has added a robust team of veterinary experts to advance research on a new stem cell technology designed to provide alternative approaches to therapy in orthopedic conditions for large and small animals. Celavet’s team of specialists is focused on restoring health and mobility to animals suffering from musculoskeletal injuries, torn ligaments and tendons, osteoarthritis, burns, and other injuries, with an initial focus on equine applications.
Veterinary Regenerative Medicine Company Celavet Launches to Develop Stem Cell Technologies for Orthopedic Conditions
Initial R&D focuses on enabling injured horses to regain
fullest potential as competitors, performers, workers or companions
OXNARD, Calif., March 20, 2008—Celavie Biosciences LLC has expanded their research on stem cell treatment to veterinary applications with a new subsidiary, Celavet Inc. Targeting the veterinary marketplace, the regenerative medicine company develops stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals, restoring health and mobility.
Celavie Biosciences Names Noted Neuroscientist Oleg Kopyov, MD, PhD Executive Vice President and Chief Scientific Officer
Kopyov will play instrumental role in R&D of stem cell technology for neurodegenerative disease applications
OXNARD, Calif., November 28, 2006—Celavie Biosciences LLC named Oleg Kopyov, MD, PhD Chief Scientific Officer and Executive Vice President to lead a team working to advance regenerative medicine beyond mainstream stem cell technology. Dr. Kopyov has been researching treatments and technologies now under development at Celavie for over 25 years. He has served as Director of Research for the California Neuroscience Institute at St. John’s Regional Medical Center in Los Angeles.
Stem Cell Technology Start-Up Celavie Biosciences Founded and Funded by Sweet Street Desserts CEO Sandy Solmon
Regenerative medicine company develops therapies for
Parkinson’s disease and other central nervous system disorders
OXNARD, Calif., April 30, 2006—Advancement in medical treatments for degenerative diseases has a new ally in Celavie Biosciences LLC, newly founded and funded by entrepreneur Sandy Solmon, CEO of Sweet Street Desserts®. The private, emerging-growth medical technology company develops stem cell-based regenerative therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS), for which there are no long-term treatments or cures.